Latest news on DiaSorin's response to COVID-19 outbreak
DiaSorin's response to COVID-19 continues through research projects that have been developed at the Saluggia and Gerenzano Centers in Italy.
In February and March, from the novel coronavirus outbreak, DiaSorin has promptly devised and developed a rapid and accurate molecular diagnostic test on our LIAISON MDX platform intended to detect all the currently known variants of the COVID-19. The test enables sample-to-answer results within less than 60 minutes compared to the 5-7 hours currently necessary to report patient results.
On April 17, DiaSorin announced that it has CE Marked the new LIAISON® SARS-CoV-2 S1/S2 IgG serological test and that it has received, on April 25, Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.
The test will respond to the need to identify the presence of antibodies in people who have been infected with SARS-CoV-2 and will be available on the 5,000 LIAISON® XL platforms installed worldwide. With a throughput of 170 patient samples per hour, the LIAISON® XL platform will support an increase in testing capacity and the availability of diagnostic testing in order to mitigate the potential impact of this virus.
On May 12, DiaSorin announced that it has obtained approval for its LIAISON® SARS-CoV-2 S1/S2 IgG test from Health Canada, the Canadian government department responsible for federal health policy. Health Canada officials acknowledged that the DiaSorin test is the first serological test to receive authorization in the country.
- From Italy 800016268
- From other countries +39 0161 1895537
Carlo Rosa, CEO DiaSorin
"The authorization of our serology test against COVID-19 in the U.S. confirms the commitment and quality of the job done by our research team in finding solutions to fight the worldwide Coronavirus pandemic. We believe that both our molecular and serology tests represent valuable and qualitative tools in diagnostics decision-making, positioning once again DiaSorin as the Diagnostic Specialist".
The fully automated serology test for the detection of SARS-CoV-2 IgG Antibodies
Video clip for media
INTERVIEW WITH CARLO ROSA, DIASORIN GROUP CEO
Quarto Grado, Rete 4, 27 March 2020
INTERVIEW WITH CARLO ROSA, CEO OF DIASORIN GROUP
DiaSorin's response to COVID-19
CNBC Class, 19 March 2020
THE TRUMP ADMINISTRATION AWARDS DIASORIN TO DEVELOP RAPID COVID-19 TESTS FOR THE NEW CORONAVIRUS WITHIN ONE HOUR
A RAPID RESPONSE MOLECULAR DIAGNOSTIC TEST FOR THE CURRENT NOVEL CORONAVIRUS (COVID-19)
DiaSorin Group has officially announced it has completed the studies for the launch of a newly effective molecular diagnostic test for COVID-19, that has been developed by the DiaSorin Research Center in Gerenzano, near Milan.